

Cytochrome2J2 (CYP2J2) Gene Polymorphism in Coronary Artery Disease

Thesis

*Submitted for Partial Fulfilment of MD Degree
in Clinical Pathology*

By

Marwa Elazab Mahmoud

M.B.B.Ch.

Master of Clinical Pathology - Ain Shams University

Supervised by

Professor/ Ghada Sadek Sabbour

Professor of Clinical Pathology

Faculty of Medicine, Ain Shams University

Professor/ Nermine Helmy Mahmoud

Professor of Clinical Pathology

Faculty of Medicine, Ain Shams University

Doctor/ Lamyaa Elsayed Allam

Lecturer of Cardiology

Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

First and foremost I would like to thank **ALLAH** the most graceful for giving me strength to accomplish this work.

I would like to express my deepest appreciation to **Professor Doctor Ghada Sadek Sabbour**, Professor of Clinical Pathology, Faculty of Medicine – Ain Shams University, for her great support, true encouragement and keen interest in the progress and accomplishment of this work. She generously devoted much of her great experience and provided unlimited support, effort and in depth guidance. I really appreciate all the encouragement and support given by her.

I am profoundly grateful to **Professor Doctor Mermine Helmy Mahmoud**, Professor of Clinical Pathology, Faculty of Medicine – Ain Shams University, for her great help, kind advice, meticulous guidance, valuable comments and careful supervision. She gave me much of her precious time, effort and knowledge. I am deeply indebted to her.

My profound appreciation to **Doctor Lamyaa Elsayed Allam**, Lecturer of cardiology, Faculty of Medicine, Ain Shams University for his great help and guidance.

My sincere thanks and deep appreciation goes to **Doctor Somia Abd Elhamid Hassan**, Lecturer of Clinical Pathology, Faculty of Medicine –Ain Shams University, for her close and kind supervision, constructive criticism, meticulous revision of the thesis and continuous advice throughout the work. I am thankful for all the time and effort she gave me.

Finally, I would like to express my deepest and greatest thanks and gratitude to my family, my husband and my princess Aya for their help, support, patience, endurance, understanding and encouragement to accomplish this work.

Marwa Elazab Mahmoud

List of Contents

Title	Page No.
List of Abbreviations	i
List of Figures	iv
List of Tables	v
Introduction	1
Aim of the Work	3
Review of Literature	
I- Coronary Artery Disease	4
A. Introduction	4
B. Epidemiology of CAD	4
C. Risk Factors of CAD	5
D. Pathogenesis of CAD	15
E. Diagnosis of CAD	19
F. Prognosis of CAD	24
II- Cytochrome P450 2J2*7 Gene Polymorphism	26
A. Structure of Cytochrome P450 2J2 Gene	26
B. Structure of CYP450 2J2 Protein	27
C. Polymorphisms of CYP2J2 and Their Effect on Enzyme Activity	28
D. Tissue Distribution of CYP450 2J2	30
E. Physiological Role of Human CYP450s and Diseases Caused by Their Defect	30
F. Regulation of CYP450 2J2	38
G. Clinical Utility of CYP2J2	41
H. Methods of Assay of CYP2J2 Gene Polymorphism	43
Subjects and Methods	50
Results	65
Discussion	79
Summary and Conclusion	85
Recommendations	88
References	89
Arabic Summary	

List of Abbreviations

Abbreviations	Full term
AA	<i>Arachidonic acid.</i>
ACE.....	<i>Angiotensin converting enzyme.</i>
ACS.....	<i>Acute coronary syndrome.</i>
AMI.....	<i>Acute myocardial infarction.</i>
ANOVA.....	<i>Analysis of variance.</i>
AP-1	<i>Activator protein-1.</i>
ARDS	<i>Acute respiratory distress syndrome.</i>
AT-1	<i>Angiotensin II type 1.</i>
BMI.....	<i>Body mass index.</i>
bp	<i>Base pair.</i>
BUN.....	<i>Blood urea nitrogen.</i>
CAD	<i>Coronary artery disease.</i>
CD14 receptor	<i>Cluster of differentiation 14 receptor .</i>
CD40L.....	<i>Cluster of differentiation 40 ligand.</i>
CK.....	<i>Creatine kinase.</i>
CK-MB.....	<i>Creatine kinase MB fraction.</i>
CNS	<i>Central nervous system.</i>
COX	<i>Cyclooxygenase.</i>
CRP.....	<i>C- reactive protein.</i>
CT	<i>Computed tomography.</i>
cTnC.....	<i>Cardic troponin C.</i>
cTnI.....	<i>Cardic troponin I.</i>
cTnT.....	<i>Cardic troponin T.</i>
CYP.....	<i>Cytochrome.</i>
ddNTPs.....	<i>Dideoxynucleotides triphosphate.</i>
DHETs.....	<i>Dihydroxyeicosatetraenoic acids.</i>
DNA	<i>Deoxyribonucleic acid.</i>
dNTPs.....	<i>Deoxynucleotide Triphosphates.</i>
ECG	<i>Electrocardiogram.</i>

List of Abbreviations (cont...)

Abbreviations	Full term
<i>EDTA K3</i>	<i>Tri-potassium ethylene di-amine- tetra-acetic acid.</i>
<i>EETs</i>	<i>Epoxyeicosatrienoic acids.</i>
<i>eNOS</i>	<i>Endothelial nitric oxide synthase.</i>
<i>EOA</i>	<i>Epoxyoctadecenoic acid.</i>
<i>EPA</i>	<i>Eicosapentaenoic acid.</i>
<i>ESC/ACC</i>	<i>European Society of Cardiology and the American College of Cardiology.</i>
<i>FFA</i>	<i>Free fatty acid.</i>
<i>g</i>	<i>Gravity.</i>
<i>HDL-C</i>	<i>High density lipoprotein Cholesterol.</i>
<i>HepG2</i>	<i>Hepatoma G2.</i>
<i>HETEs</i>	<i>Hydroxy-eicosatetraenoic acids.</i>
<i>hsCRP</i>	<i>high Sensitivity C-Reactive Protein.</i>
<i>ICAM-1</i>	<i>Intercellular adhesion molecule 1.</i>
<i>IL-6</i>	<i>Interleukin – 6.</i>
<i>IQR</i>	<i>Interquartile range.</i>
<i>kb</i>	<i>kilo base pair.</i>
<i>kDa</i>	<i>Kilodalton .</i>
<i>LA</i>	<i>Linolenic acid.</i>
<i>LDL-C</i>	<i>Low density lipoprotein cholesterol.</i>
<i>let-7b</i>	<i>Lethal 7b.</i>
<i>LOX</i>	<i>Lipoxygenase.</i>
<i>LTs</i>	<i>Leukotrienes.</i>
<i>MALDI-TOF</i>	<i>Matrix assisted laser desorption ionization time of flight.</i>
\bar{x}	<i>Mean.</i>
<i>miRNAs</i>	<i>MicroRNAs.</i>
<i>MMPs</i>	<i>Matrix metalloproteinases.</i>

List of Abbreviations (cont...)

Abbreviations	Full term
<i>MPO</i>	<i>Myeloperoxidase.</i>
<i>mRNA</i>	<i>Messenger ribonucleic acid.</i>
<i>MS</i>	<i>Mass spectrometry.</i>
<i>NF-κB</i>	<i>Nuclear factor- κB.</i>
<i>NO</i>	<i>Nitric oxide.</i>
<i>P</i>	<i>Probability.</i>
<i>PCR</i>	<i>Polymerase chain reaction.</i>
<i>PCR-RFLP</i>	<i>Polymerase chain reaction and restriction fragment length polymorphism.</i>
<i>PGs</i>	<i>Prostaglandins.</i>
<i>PLGF</i>	<i>Placental growth factor.</i>
<i>PUFAs</i>	<i>Polyunsaturated fatty acids.</i>
<i>RPM</i>	<i>Revolutions per minute.</i>
<i>Rs</i>	<i>Reference sequence</i>
<i>sCD40L</i>	<i>Soluble CD40 ligand.</i>
<i>SD</i>	<i>Standard deviation.</i>
<i>sEH</i>	<i>Soluble epoxide hydrolase .</i>
<i>SNPs</i>	<i>Single nucleotide polymorphisms.</i>
<i>Sp1</i>	<i>Specificity protein 1.</i>
<i>T2DM</i>	<i>Type 2 Diabetes Mellitus.</i>
<i>TC</i>	<i>Total cholesterol.</i>
<i>TG</i>	<i>Triglycerides.</i>
<i>TNF-α</i>	<i>Tumor necrosis factor α</i>
<i>TXs</i>	<i>Thromboxanes.</i>
<i>3' UTR</i>	<i>3 prime untranslated region.</i>
<i>WHO</i>	<i>World Health Organization.</i>
<i>Xα</i>	<i>Active factor X.</i>
<i>μL</i>	<i>Microliter.</i>

List of Figures

Figure No.	Title	Page No.
Figure (1):	Metabolic syndrome as a risk factor for atherosclerosis	7
Figure (2):	Mechanism of action of CD40L	14
Figure (3):	Fatty-streak formation.....	17
Figure (4):	Formation of an advanced, complicated lesion of atherosclerosis	17
Figure (5):	The vulnerable plaque and consequences of plaque rupture	18
Figure (6):	The pattern of different cardiac markers	24
Figure (7):	Genetic location of CYP2J2 gene	27
Figure (8):	Gel electrophoresis shows lane 1 and 4 are wild type with a non-digested band at 242 bp, lane 2 is a ladder (50bp) and lane 3 with heterozygous mutation of CYP2J2*7 (G50T) with a digested bands at 99 bp, 143bp and non- digested band at 242 bp.....	58
Figure (9):	Pie chart showing percentage of distribution of one, two and three vessel disease in CAD patients group.....	69

List of Tables

Table No.	Title	Page No.
Table (1):	Risk factors of CAD.....	5
Table (2):	CYP2J2 allele and enzyme activity.....	29
Table (3):	Forward and reverse primers sequence.....	56
Table (4):	PCR reaction components.	56
Table (5):	Cycling protocol.	57
Table (6):	Restriction protocol.....	57
Table (7):	Descriptive and Comparative Statistics of Demographic Data in the CAD Patients' group and Control group using Chi-square test for categorized data and Student t test for quantitative parametric data	68
Table (8):	Descriptive Statistics of the Clinical Characteristics of CAD patients' Group.....	69
Table (9):	Descriptive and comparative statistics of the CAD Patients' Group and Control Group regarding the Different Studied Laboratory Parameters using Student t test for Parametric data.....	70
Table (10):	Descriptive Statistics of the Genotypes Frequencies of the CYP 2J2*7 Gene SNP (G50T) in the CAD Patients' Group and Control Group	71
Table (11):	Comparative Statistics of the Genotypes Frequencies of the CYP2J2*7 Gene SNP (G50T) in the CAD Patients' Group and Control Group using Fisher exact test	71
Table (12):	Descriptive Statistics of Allele Frequencies of the CYP 2J2*7 Gene SNP (G50T) in the CAD Patients' Group and Control Group	72
Table (13):	Comparative Statistics of Allele Frequencies of the CYP 2J2*7 Gene SNP (G50T) in the CAD Patients' Group and Control Group using Fisher exact test	72

List of Tables

Table No.	Title	Page No.
Table (14):	Descriptive and Comparative Statistics of CYP2J2*7 (G50T) Genotypes regarding the Risk Factors of CAD using Fisher exact test	73
Table (15):	Descriptive and Comparative Statistics of CYP2J2*7 (G50T) Genotypes regarding Lipid profile in CAD Patients' Group using Student t test for Quantitative Parametric Data	74
Table (16):	Descriptive and Comparative Statistics of CYP2J2*7 (G-50T) Genotypes regarding Gensini Score in CAD Patients' Group using Mann-Whitney U test for Quantitative Nonparametric data.....	75
Table (17):	Descriptive and Comparative Statistics of the Clinical Characteristics in CAD Patients' Subgroups using Fisher exact test for Qualitative data, one way ANOVA test for Quantitative Parametric Data and Kruskal –Wallis test for Quantitative Non parametric data.....	76
Table (18):	Descriptive and Comparative Statistics of Lipid Profile in CAD Patients' Subgroups using One Way ANOVA.....	77
Table (19):	Descriptive and Comparative Statistics of the Genotypes Frequencies of the CYP 2J2*7 Gene SNP (G50T) in One, Two and Three Vessel Disease Patient's Subgroups using Fisher exact test	78
Table (20):	Descriptive and Comparative Statistics of the Allele Frequencies of the CYP 2J2*7 Gene SNP (G50T) in One, Two and Three Vessel Disease Patient's Subgroups using Fisher exact test	78

INTRODUCTION

Coronary artery disease (CAD) is a major cause of morbidity and mortality worldwide (*Bangalore and Messerli, 2006*). Although CAD mortality rates worldwide have declined over the past four decades, CAD remains responsible for about one-third or more of all deaths in individuals over age 35 (*Nichols et al., 2014*).

In Egypt, according to World Health Organization (WHO) regional office report, there is an increased prevalence of coronary heart disease which is responsible for about 23.14% of all deaths among Egyptians (*Mendis et al., 2014*).

Acute cardiovascular events are thought to be ultimately caused largely by an inflammation-mediated destabilization and rupture of atherosclerotic lesions (*Stoll and Bendszus, 2006*). It is also generally accepted that coronary artery disease is a complex polygenic disease resulting from the interaction between genetic variation and environmental factors (*Flossmann et al., 2013*). There are some traditional factors that increase the risk of coronary artery disease such as hypertension and smoking, but genetic risk factors, suggested by evidence from inheritance-based studies, also contribute to a predisposition to coronary artery disease (*Choi, 2015*).

CYP2J2 is a member of the cytochrome P450 (CYP) family of monooxygenases. In humans, it is the sole member of the CYP2J subfamily (*Ma et al., 2009*). Specifically, CYP2J2 is an epoxide-forming enzyme that catalyzes epoxide formation at the site

of a carbon–carbon double bond in the substrate, as other CYP epoxygenases do, such as CYP2C8 and CYP2C9 (*Spiecker et al., 2010*).

The CYP2J2 is abundantly expressed in coronary artery endothelial and smooth muscle cells and in cardiac myocytes. Other tissues, including the liver, kidneys, lungs, pancreas and gastrointestinal tract also express CYP2J2 (*Wu et al., 2012*).

Arachidonic acid is metabolized in endothelial cells by cytochrome P450 epoxygenases into four epoxyeicosatrienoic acids (EETs; 5, 6-EET, 8, 9-EET, 11, 12-EET and 14, 15-EET) (*Node et al., 2011*). Accumulating evidence indicates that CYP epoxygenase-derived EETs exert diverse cardiovascular protective effects including antiapoptotic effects in endothelial cells, anti-inflammatory effects by inhibiting endothelial nuclear factor- κ B (NF- κ B), antiangiogenic effects and upregulation of endothelial nitric oxide synthase (eNOS) expression and activity, all of which suggest a potential anti-atherosclerotic effects of CYP epoxygenase-derived EETs that may be beneficial against coronary artery disease (*Oltman et al., 2013*).

A large degree of inter-individual variation in CYP2J2 expression has been observed. Among the factors known to be associated with different human cytochrome P450 gene expression are genetic polymorphisms (*Wolf et al., 2010*). In CYP2J2, the G-50T (CYP2J2*7) (rs890293) polymorphism in the proximal promoter disrupts specificity protein 1 (Sp1) transcription factor binding site and leads to reduced CYP2J2 transcription (*Campbell et al., 2014*).

AIM OF THE WORK

The aim of the present study is to investigate the association between G-50T (CYP2J2*7) (rs890293) gene polymorphism and ischemic coronary artery disease.

CORONARY ARTERY DISEASE

A. Introduction:

Coronary artery disease (CAD) is the commonest cause of heart attacks, which occur when blood flow to the myocardium is interrupted (*Antman et al., 2012*). The clinical presentations of CAD include stable angina pectoris, acute coronary syndrome (unstable angina, myocardial infarction), heart failure and sudden death (*Kastrup, 2013*).

B. Epidemiology of CAD:

Cardiovascular diseases cause more deaths per year than the next four leading causes of death combined (cancer, chronic lower respiratory diseases, accidents and diabetes mellitus) (*Thom and Haase, 2010*).

CAD prevalence is increasing and is expected to become the dominant cause of mortality worldwide, reaching 23.4 million in 2030. CAD accounted for 30.8% deaths or 1 of every 3 deaths in the United States (*Dariush et al., 2016*).

In Egypt, according to World Health Organization (WHO) regional office report, there is an increased prevalence of coronary heart disease which is responsible for about 23.14% of all deaths among Egyptians (*Mendis et al., 2014*).

C. Risk Factors of CAD:

Risk factors for CAD are either modifiable by changing lifestyle, daily habits and by medical treatment, or non-modifiable risk factors, they cannot be altered through lifestyle habits as shown in Table (1) (*Chogle and Chakravarty, 2009*).

Table (1): Risk factors of CAD

Modifiable	<ul style="list-style-type: none"> - Smoking - Hypertension - Dyslipidemia - Obesity - Metabolic syndrome and diabetes mellitus - Physical inactivity
Non Modifiable	<ul style="list-style-type: none"> - Age - Sex and Menopausal Status - Genetic predisposition and family history
Non-traditional	<ul style="list-style-type: none"> - Infections - Stress and depression - Homocysteine - Fibrinogen

(*Apple et al., 2008*)

1) Modifiable Risk Factors:

a) Smoking:

Smoking participates in the pathogenesis of coronary artery disease and sudden death by different mechanisms, including the promotion of atherosclerosis, the stimulation of coronary thrombosis and cardiac arrhythmias through reducing oxygen carrying capacity of the blood (*Lavi et al., 2011*).